AbbVie Opens Expanded Manufacturing Facility in Sligo, Ireland
€85 million investment creates greater manufacturing capacity to deliver new medicines for patients
The Chairman and CEO of AbbVie Inc. Richard A. Gonzalez officially opened the company's newly expanded facility in Sligo, Ireland. The site is a strategic asset for AbbVie due to its involvement in the commercialization and manufacturing of AbbVie pipeline products in liver disease, oncology and women's health. The expansion provides increased manufacturing capacity to deliver on AbbVie's existing portfolio of medicines and to support potential new therapies within AbbVie's pipeline.
Since the initial announcement of the expansion in 2012, AbbVie has invested €85 million in the Sligo facility, resulting in the creation of up to 175 highly skilled jobs in Sligo. The new jobs include roles in engineering, quality, pharmaceutical science and other science-based areas. The investment has been supported by the Irish Government through IDA Ireland.
"This investment represents our ongoing commitment to Sligo and Ireland as an important part of AbbVie's biopharmaceutical manufacturing strategy," said Azita Saleki-Gerhardt, Ph.D., Senior Vice President, Operations, AbbVie. "Our presence here in Sligo dates back to 1974, and our success in Ireland is a credit to our dedicated staff and management. This expansion builds capacity for existing products and for potential therapies in our pipeline, such as our investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection."
Other news from the department manufacturing
